Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-Blinded Study of the Efficacy and Safety of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction (OBD)

NCT00595946 is registered in ClinicalTrials.gov with Sucampo Pharma Americas, LLC as lead sponsor.

NCT NCT00595946
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00595946 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-Blinded Study of the Efficacy and Safety of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction (OBD)
Lead sponsor
Sucampo Pharma Americas, LLC
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2007
Completion date
March 31, 2009
Enrollment
439 (actual)
Sites
95

Conditions

As the registry lists them; a condition with its own page is linked.

opioid-induced bowel dysfunction